1.Liu M, Zhang D, Wang D, Wu X, Zhang Y, Yin J, Zhu G*. Cost-effective In vivo and In vitro Mouse Models for Evaluating Anti-Cryptosporidial Drug Efficacy: Assessing Vorinostat, Docetaxel and Baicalein. J Infect Dis. 2023 Jul 7:jiad243.
2.Yang B, Yan Y, Wang D, Zhang Y, Yin J, Zhu G. On-target inhibition of Cryptosporidium parvum by nitazoxanide (NTZ) and paclitaxel (PTX) validated using a novel MDR1-transgenic host cell model and algorithms to quantify the effect on the parasite target. PLoS Negl Trop Dis. 2023 Mar 27;17(3):e0011217
3.Wang D, Wang C, Zhu G. Genomic reconstruction and features of glycosylation pathways in the apicomplexan Cryptosporidium parasites. Front Mol Biosci. 2022 Nov 17;9:1051072.
4.Gao X#, Yin J#, Wang D, Li X, Zhang Y, Wang C, Zhang Y, Zhu G.Discovery of New Microneme Proteins in Cryptosporidium parvum and Implication of the Roles of a Rhomboid Membrane Protein (CpROM1) in Host-Parasite Interaction.Front Vet Sci.2021;8:778560
5.Li X#, Yin J#, Wang D, Gao X, Zhang Y, Wu M, Zhu G. The mucin-like, secretory type-I transmembrane glycoprotein GP900 in the apicomplexanCryptosporidium parvumis cleaved in the secretory pathway and likely plays a lubrication role. Parasit Vectors. 2022 May 17;15(1):170
6.Zhang T, Gao X, Wang D, Zhao J, Zhang N, Li Q, Zhu G, Yin J*. A Single-Pass Type I Membrane Protein from the Apicomplexan ParasiteCryptosporidium parvumwith Nanomolar Binding Affinity to Host Cell Surface. Microorganisms. 2021 May 8;9(5):1015.
7.Nie J#, Yin J#, Wang D, Wang C, Zhu G. Implication of Potential Differential Roles of the Two Phosphoglucomutase Isoforms in the Protozoan ParasiteCryptosporidium parvum. Pathogens. 2021 Dec 24;11(1):21
8.Zhu G, Yin J, Cuny GD.Current status and challenges in drug discovery against the globally important zoonotic cryptosporidiosis.Animal Diseases.2021；1:3
